I. The Three Viruses: Shared Biology, Distinct Complications

Chikungunya virus (CHIKV), dengue virus (DENV), and West Nile virus (WNV) are arthropod-borne RNA viruses. The source paper treats them together because they share vector-mediated transmission, an acute infection phase, and the possibility of serious inflammatory consequences. Their clinical manifestations, however, differ significantly. The framework therefore distinguishes a shared conceptual architecture from virus-specific research questions.

Chikungunya is associated with fever and potentially persistent joint pain. Dengue can progress to vascular leakage, bleeding, and shock. West Nile infection may involve the central nervous system, including encephalitis, meningitis, and acute flaccid paralysis. These differences matter: a single intervention cannot be presumed to have the same safety profile or outcome across all three diseases.

The proposed coherence interpretation describes infection as a disturbance involving pathogen activity, host immune regulation, and tissue-specific recovery. “Coherence collapse” is the author’s proposed systems-level description, not a validated clinical biomarker or an established infectious-disease diagnosis.

Comparative clinical landscape

II. Two-System Conceptual Architecture

The private research paper distinguishes two proposed components. The first is a host-directed coherence concept intended to investigate immune regulation, inflammatory resolution, vascular function, and tissue recovery. It discusses photobiomodulation (PBM), pulsed electromagnetic fields (PEMF), and a frequency-associated coherence hypothesis. These are proposed research avenues, not established antiviral therapies for chikungunya, dengue, or West Nile virus.

The second is a pathogen-directed acoustic concept, represented by the proposed Frequency Sweep Device (FSD-1). The working hypothesis is that physical properties of some viral particles might permit selective acoustic interaction under carefully controlled laboratory conditions. Whether such selectivity exists for the three viruses, and whether it could be translated into a safe clinical intervention, remains unproven.

The source cites Veras and colleagues (2026) as an in-vitro point of departure for ultrasound effects on other enveloped respiratory viruses. Such observations cannot establish efficacy for arboviruses or demonstrate safe energy delivery within the human body. Direct testing, independent replication, and rigorous exposure safety assessment would be prerequisites for any further claim.

The two proposed systems are conceptually distinct. A host-response hypothesis should not be presented as proof of pathogen inactivation, and an in-vitro particle effect should not be presented as evidence of clinical recovery. Neither is a substitute for standard medical care.

III. Five-Fluid Research Platform

The private paper identifies five named candidate fluid families. The public architecture preserves their research roles without disclosing ingredients, concentrations, preparation procedures, imprinting parameters, administration routes, or dosing schedules. Their names describe proposed development programs, not approved medicines.

ArboFlux is proposed as the shared arboviral platform. HemoFlux is associated with blood and vascular-support questions relevant to dengue. ArthroFlux concerns joint-related outcomes after chikungunya. MyoFlux concerns muscle symptoms and recovery. BarriFlux concerns neurovascular and blood–brain barrier questions associated with West Nile virus.

For every candidate, the first scientific questions are composition characterization, batch consistency, stability, contamination control, interaction risk, and whether any measurable biological effect exists beyond appropriate controls. Clinical efficacy has not been established. The private formulations and manufacturing information are withheld under NDA.

Public architecture catalog

IV. Virus-Specific Research Frameworks

For chikungunya, the proposed program distinguishes acute viral illness from persistent inflammatory joint symptoms. Outcomes of interest include physician-assessed symptom burden, physical function, inflammatory measures, and long-term recovery. The source hypothesizes that host-directed modulation could be investigated as an adjunct, but does not establish a treatment effect.

For dengue, the priority is safety. Severe dengue can involve dangerous plasma leakage and bleeding. Any experimental program would require specialist oversight, careful monitoring, and explicit exclusion of approaches that might worsen bleeding, fluid balance, or hemodynamic stability. No investigational device or formulation described in the paper has been shown to prevent severe dengue.

For West Nile virus, the framework addresses neurological injury and recovery as distinct research endpoints. The presence of neuroinvasive disease requires established clinical management. A proposed blood–brain barrier or neural-coherence intervention cannot be assumed to reach the central nervous system or improve outcomes without direct evidence.

Across all three conditions, the paper’s proposed adjunctive approaches remain hypotheses. The public version intentionally does not reproduce patient-facing schedules or individualized intervention instructions.

V. Unified Comparative Protocol Matrix

The unifying logic of the private paper is retained below as a research matrix, not a clinical protocol. It links each infection to its principal complication, the corresponding proposed coherence question, and the evidence required to evaluate that question.

Research matrix

VI. Fever, Inflammation, and Supportive Care

Fever and inflammation are important components of host responses to infection. Their management depends on the specific disease, clinical condition, and professional assessment. The source proposes a coherence interpretation of the inflammatory response, but that interpretation has not been validated as a basis for altering fever treatment.

Dengue in particular requires careful management of bleeding risk and hydration. The public research framework does not authorize withholding medical evaluation, changing prescribed therapy, substituting experimental fluids for clinical hydration, or applying untested physical-field exposures during acute infection.

A credible future program would distinguish biological markers from patient-important outcomes such as hospitalization, complications, neurological function, joint disability, and survival. No numerical outcome in the private model should be treated as a demonstrated patient benefit.

VII. Acoustic Selectivity and Targeted-Frequency Research

The source identifies a long-term research objective: determine whether acoustic interactions with viral particles are reproducible, distinguishable from effects on host materials, and sufficiently selective to justify further study. This is a sequence of unanswered questions rather than a known operating principle.

Key uncertainties include whether a proposed resonant signature is reproducible across viral strains and biological environments; whether an effect observed in a simplified laboratory sample persists in complex tissue; whether energy delivery can be measured and controlled safely; and whether the relevant biological endpoint reflects true loss of infectivity rather than a change in particle appearance.

The exact device bandwidth, drive levels, acoustic exposure conditions, control algorithms, targeting parameters, and experimental execution details remain private. The public edition provides no build specification or operational exposure procedure.

VIII. Staged Validation and Regulatory Pathway

The source organizes development into an early preclinical stage followed by increasingly demanding validation and clinical research phases. At the conceptual level, the sequence begins with independent characterization of candidate interventions, proceeds through safety and reproducibility assessment, and advances only when pre-specified evidence supports doing so.

Any studies involving infectious agents must be designed and conducted by qualified institutions under the applicable biosafety, ethics, and regulatory requirements. The present document does not provide instructions for culturing, propagating, concentrating, or experimentally manipulating pathogens.

Before clinical research, investigators would need an independently reviewed safety case, appropriate regulatory authorization, validated manufacturing controls for any administered product, and a study protocol with suitable comparators and meaningful endpoints. Negative findings should terminate or redirect a proposed mechanism rather than be explained away.

IX. Thirteen Falsifiable Research Predictions

The private edition presents thirteen predictions. For public disclosure, the research questions are preserved at a non-operational level; private thresholds, device settings, intervention schedules, and experimental execution details are omitted. The items below are hypotheses, not observed results.

Research questions

X. Objections, Safety Questions, and Evidence Hierarchy

The central objection is straightforward: there is no clinical evidence that the proposed FSD-1 system treats chikungunya, dengue, or West Nile infection. Evidence from ultrasound experiments on other viruses does not establish cross-virus efficacy or safe in-body delivery. The framework must remain falsifiable and should be abandoned or revised where tests fail.

The source also discusses botanical and nutritional candidate components. Some published work is preclinical or in-vitro, which cannot establish human efficacy or safe dosing for acute viral illness. Particular attention is required for bleeding risk, mineral and electrolyte disturbances, blood pressure effects, medication interactions, liver or kidney impairment, and cumulative exposure from multiple candidate products.

The evidence hierarchy is: established clinical management and accepted infectious-disease biology; independently replicated preclinical findings for the precise candidate and target; appropriately designed human safety research; and finally controlled clinical efficacy studies. The CHRISTOS® coherence interpretation and its proposed device/fluid architecture remain at the hypothesis stage unless supported by those later levels of evidence.

No reader should infer that the term “frequency,” “resonance,” “structured water,” or “coherence” by itself establishes an antiviral mechanism. The necessary causal pathway must be demonstrated with appropriate controls.

XI. Conclusion

This public edition preserves the source paper’s central distinction between host-directed and pathogen-directed hypotheses, its three-virus comparative structure, its five named fluid research families, and its staged validation logic. It does not claim an approved treatment, an effective antiviral device, or a clinically validated coherence intervention.

The most consequential unresolved questions are selective physical interaction, biological relevance, exposure safety, and clinical benefit. Each is independently testable. Until such evidence exists, established clinical care remains essential, and the CHRISTOS® proposals are research concepts only.

References & Source Notes

The following references are transcribed in abbreviated form from the supplied private manuscript. Bibliographic details and the underlying scientific claims should be independently checked before formal scientific submission. A cited result in another disease or virus does not validate the CHRISTOS® proposal.

Chagas, T. G., et al. (2024). Long chikungunya? An overview of the immunopathology of persistent arthralgia.

Huan, C., et al. (2021). Research progress on the antiviral activity of glycyrrhizin and its derivatives in liquorice. Frontiers in Pharmacology, 12, 680674.

Jayasekara, K. G., et al. (2024). Anti-dengue viral activity of Glycyrrhiza glabra roots in Vero cells. Scientific Reports.

Krawitz, C., et al. (2011). Inhibitory activity of a standardized elderberry liquid extract against clinically relevant human respiratory bacterial pathogens and influenza A and B viruses. BMC Complementary and Alternative Medicine, 11, 16.

Langerman, S. D., & Ververs, M. (2020). Micronutrient supplementation and clinical outcomes in patients with dengue fever. American Journal of Tropical Medicine and Hygiene, 104(1), 45–51.

Poo, Y. S., et al. (2014). Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection. PLoS Neglected Tropical Diseases, 8(12), e3354.

Porter, R. S., & Bode, R. F. (2017). A review of the antiviral properties of black elder (Sambucus nigra L.) products. Phytotherapy Research, 31(4), 533–554.

Shrivastava, N., et al. (2019). Zinc chelation specifically inhibits early stages of dengue virus replication by activation of NF-κB and induction of antiviral response in epithelial cells. Frontiers in Immunology, 10, 2347.

Stoermer, K. A., et al. (2012). Genetic ablation of arginase 1 in macrophages and neutrophils enhances clearance of an arthritogenic alphavirus. Journal of Immunology, 189(8), 4047–4059.

Veras, F. P., et al. (2026). Ultrasound effectively destabilizes and disrupts the structural integrity of enveloped respiratory viruses. Scientific Reports, 16, 8612.

Intellectual Property & Public Disclosure

Public version only. Withheld under NDA: all candidate fluid ingredients and concentrations, preparation and imprinting methods, administration schedules, patient dosing, FSD-1 component specifications and acoustic output settings, device calibration, detailed laboratory execution procedures, proprietary decision criteria, and all protected Mathematics of Reality (MoR-144) equations and implementation constants. No source code, manufacturing recipe, or operational treatment protocol is published here.

© 2026 Joshua Farrior / CHRISTOS® Energy, Technology & Harmonic Design Consulting, LLC. All rights reserved. This page is a public conceptual research disclosure, not a clinical treatment manual or an offer of an approved medical product.